Zoetis Services LLC

John Keith Garrett

Gregory Paul Nitzel

Jeffrey E Galvin

James R Kulawik, Ii

Tracy L Ricker

Megan Marie Smutzer

James R Ii Kulawik

This invention provides a combination vaccine which includes a porcine circovirus type 2 (PCV2) antigen and a cell free(M. hyo) culture supernatant for protecting a pig against PCV2 and M. hyo infections, wherein the M. hyo culture supernatant is substantially free of PCV2 antibodies.

PCV/mycoplasma hyopneumoniae vaccine

This invention provides a(M. hyo) antigen that is compatible with antigens from other swine pathogens, wherein the M. hyo antigen is a cell free M. hyo culture supernatant which is substantially free of swine IgG.

Mycoplasma hyopneumoniae vaccine

This invention provides a combination of a first vaccine comprising a porcine circovirus type 2 (PCV2) antigen and a() culture supernatant and a second vaccine comprising a porcine reproductive and respiratory syndrome (PRRS) virus antigen, for treating an animal against an infection with PCV2, an infection with, and an infection with PRRS virus, wherein theculture supernatant has been separated from insoluble cellular material and is substantially free of both IgG and immunocomplexes comprised of antigen bound to immunoglobulin.

PCV/vaccine for use with PRRSV vaccine

This invention provides a protein-A or protein-G treated(M.hyo) antigen that is compatible with antigens from other swine pathogens, wherein the M.hyo antigen is an M.hyo culture supernatant.

vaccine

This invention provides an immunogenic composition including the supernatant of a() culture, wherein the supernatant of theculture has been separated from insoluble cellular material by centrifugation, filtration, or precipitation and is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

This invention provides a multivalent immunogenic composition including a soluble portion of a(M.hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and aantigen, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

PCV/mycoplasma hyopneumoniae/lawsonia intracellularis combination vaccine

This invention provides a trivalent immunogenic composition including a soluble portion of a(M.hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a PRRS virus antigen, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

PCV/mycoplasma hyopneumoniae/PRRS combination vaccine

This invention provides a multivalent immunogenic composition including a soluble portion of a(M. hyo) whole cell preparation; and a porcine circovirus type 2 (PCV2) antigen, wherein the soluble portion of the M. hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

[object Object]

This invention provides an immunogenic composition including a soluble portion of a(M.hyo) whole cell preparation, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

This invention provides a trivalent immunogenic composition including a soluble portion of a() whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a PRRS virus antigen, wherein the soluble portion of thepreparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

This invention provides a multivalent immunogenic composition including a soluble portion of a() whole cell preparation; and a porcine circovirus type 2 (PCV2) antigen, wherein the soluble portion of thepreparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

Growing community of inventors

North Wilkesboro, NC, United States of America

John Keith Garrett